These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 4480369)
41. Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. Kauppila A; Jänne O; Kujansuu E; Vihko R Cancer; 1980 Nov; 46(10):2162-7. PubMed ID: 6253041 [TBL] [Abstract][Full Text] [Related]
42. A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer. Collis CH Br J Clin Pract; 1978 May; 32(5):139-44. PubMed ID: 666968 [No Abstract] [Full Text] [Related]
43. Progestin therapy in lesions of the endometrium. Wentz WB Semin Oncol; 1985 Mar; 12(1 Suppl 1):23-7. PubMed ID: 3975648 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of in vivo and in vitro responses of endometrial adenocarcinoma to progestins. Holinka CF; Deligdisch L; Deppe G; Fleming H; Namit C; de la Pena MM; Gurpide E Adv Exp Med Biol; 1981; 138():365-76. PubMed ID: 6211063 [No Abstract] [Full Text] [Related]
46. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate. Lovecchio JL; Averette HE; Lichtinger M; Townsend PA; Girtanner RW; Fenton AN Obstet Gynecol; 1984 Apr; 63(4):557-60. PubMed ID: 6538327 [TBL] [Abstract][Full Text] [Related]
48. Oral progestogens and adenocarcinoma of the uterus. An account of 3 cases of advanced endometrial carcinoma treated with an oral progestogen. Phillips TJ J Obstet Gynaecol Br Commonw; 1966 Jun; 73(3):487-9. PubMed ID: 5947437 [No Abstract] [Full Text] [Related]
49. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Mortel R; Zaino R; Satyaswaroop PG Cancer; 1984 Jan; 53(1):113-6. PubMed ID: 6689993 [TBL] [Abstract][Full Text] [Related]
50. [Combination of antimetabolites and alkylating agents in the treatment of advanced breast cancer]. Germiniani R; Pipino G; Lavorato F; Bressani Doldi S Minerva Med; 1977 Mar; 68(13):831-4. PubMed ID: 321989 [TBL] [Abstract][Full Text] [Related]
51. Combination chemotherapy with methotrexate (NSC-740), adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and 5-fluorouracil (NSC19893) for adult solid tumors. Stephens RL; Hoogstraten B Cancer Chemother Rep; 1974; 58(6):943-5. PubMed ID: 4614901 [No Abstract] [Full Text] [Related]
52. Current cancer chemotherapy in obstetrics and gynecology. Bloomfield RD Am J Obstet Gynecol; 1971 Feb; 109(3):487-528. PubMed ID: 4324086 [No Abstract] [Full Text] [Related]
53. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Tropé C; Johnsson JE; Simonsen E; Christiansen H; Cavallin-Ståhl E; Horváth G Am J Obstet Gynecol; 1984 Jun; 149(4):379-81. PubMed ID: 6539567 [TBL] [Abstract][Full Text] [Related]
54. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Horton J; Elson P; Gordon P; Hahn R; Creech R Cancer; 1982 Jun; 49(12):2441-5. PubMed ID: 7074558 [TBL] [Abstract][Full Text] [Related]
55. A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. Smalley RV; Bartolucci AA; Hemstreet G; Hester M J Urol; 1981 Feb; 125(2):191-5. PubMed ID: 7206052 [TBL] [Abstract][Full Text] [Related]
56. [Effect of progestagens on neoplastic tissue and endometrium in patients with diagnosed uterine corpus cancer]. Swiatkowska H; Sikorowa L; Teter J; Tarlowska L; Zieliński J Ginekol Pol; 1975 Jul; 46(7):761-8. PubMed ID: 168129 [No Abstract] [Full Text] [Related]
57. Chemotherapy of ovarian cancer. Fisher RI; Young RC Surg Clin North Am; 1978 Feb; 58(1):143-50. PubMed ID: 417411 [No Abstract] [Full Text] [Related]
58. [Progestational hormones and cancer of the endometrium]. Lambotte R; Hustin J Rev Med Liege; 1973 Oct; 28(19):662-7. PubMed ID: 4767877 [No Abstract] [Full Text] [Related]
59. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs. Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635 [TBL] [Abstract][Full Text] [Related]
60. [Chemotherapy in advanced cancer of the lung]. Fleischer I; Wainstein R; Jovtis SL; Gibson AM; Barousse AP Medicina (B Aires); 1979; 39(4):472-6. PubMed ID: 545078 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]